Immunogenicity 9969

summary
Sample ID
3812
Response
Negative
Tumor Type
Bile duct cancer
Gene Symbol
PEX6
Transcript ID
ENST00000244546
HLA INFO
B*35:03
TCR INFO

No TCR info found!

T cell Tumor cell B*35:03
sequence
Full length protein sequence (738 aa)
MALAV
1
LRVLE
6
PFPTE
11
TPPLA
16
VLLPP
21
GGPWP
26
AAELG
31
LVLAL
36
RPAGE
41
SPAGP
46
ALLVA
51
ALEGP
56
DAGTE
61
EQGPG
66
PPQLL
71
VSRAL
76
LRLLA
81
LGSGA
86
WVRAR
91
AVRRP
96
PALGW
101
ALLGT
106
SLGPG
111
LGPRV
116
GPLLV
121
RRGET
126
LPVPG
131
PRVLE
136
TRPAL
141
QGLLG
146
PGTRL
151
AVTEL
156
RGRAR
161
LCPES
166
GDSSR
171
PPPPP
176
VVSSF
181
AVSGT
186
VRRLQ
191
GVLGG
196
TGDSL
201
GVSRS
206
CLRGL
211
GLFQG
216
EWVWV
221
AQARE
226
SSNTS
231
QPHLA
236
RVQVL
241
EPRWD
246
LSDRL
251
GPGSG
256
PLGEP
261
LADGL
266
ALVPA
271
TLAFN
276
LGCDP
281
LEMGE
286
LRIQR
291
YLEGS
296
IAPED
301
KGSCS
306
LLPGP
311
PFARE
316
LHIEI
321
VSSPH
326
YSTNG
331
NYDGV
336
LYRHF
341
QIPRV
346
VQEGD
351
VLCVP
356
TIGQV
361
EILEG
366
SPEKL
371
PRWRE
376
MFFKV
381
KKTVG
386
EAPDG
391
PASAY
396
LADTT
401
HTSLY
406
MVGST
411
LSPVP
416
WLPSE
421
ESTLW
426
SSLSP
431
PGLEA
436
LVSEL
441
CAVLK
446
PRLQP
451
GGALL
456
TGTSS
461
VLLRG
466
PPGCG
471
KTTVV
476
AAACS
481
HLGLH
486
LLKVP
491
CSSLC
496
AESSG
501
AVETK
506
LQAIF
511
SRARR
516
CRPAV
521
LLLTA
526
VDLLG
531
RDRDG
536
LGEDA
541
RVMAV
546
LRHLL
551
LNEDP
556
LNSCP
561
PLMVV
566
ATTSR
571
AQDLP
576
ADVQT
581
AFPHE
586
LEVPA
591
LSEGQ
596
RLSIL
601
RALTA
606
HLPLG
611
QEVNL
616
AQLAR
621
RCAGF
626
VVGDL
631
YALLT
636
HSSRA
641
ACTRI
646
KNSGL
651
AGGLT
656
EEDEG
661
ELCAA
666
GFPLL
671
AEDFG
676
QALEQ
681
LQTAH
686
SQAVG
691
APKVE
696
TKSLE
701
CLPGP
706
GLQLH
711
ALSSL
716
MNWTL
721
WPQAG
726
GEVEI
731
LEE
736
Mutation Information
DNA mutation:
None
Peptide Range:
694 ~ 718
Mut AA position:
706 (13 in Wild Type peptide)
Alignment
Wild Type:
"VGAPKVETKSLECLPGPGLQLHALS
||||||||||||.||||||||||||
Mutant:
VGAPKVETKSLEWLPGPGLQLHALS"
reference

Science, 2015

Immunogenicity of somatic mutations in human gastrointestinal cancers

Gene Name (from Reference) PEX6

clinic trial
Checkpoint Blockade

None

ACT

None

Vaccination

None

Curative Effect

None

experiment
minimal_peptide

None

Antigen Type

TMG RNA

T-cell Source

TILs

APC Type

None

Assay

IFNg ELISPOT assay